Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment

Summary

The purpose of this study is to determine whether it is feasible and safe to give research participants investigational treatment with durvalumab and tremelimumab after they have completed standard treatment for NSCLC and once they have detectable circulating tumor DNA (ctDNA) in the blood before there is evidence of disease recurrence on imaging studies. These investigational agents are a type of immunotherapy, which is a treatment that activates your own body's immune system to treat cancer.

Timeline

Start

2022-12

Primary completion

2023-07

Completion

2023-12

Outcome

Outcome not reported

Stopped: “Contract was never finalized.”

Drugs

Indications